Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The incidence of cancer pain increases in discharged patients because of discontinued standard treatments and reductions in medication compliance. Motivated by the need for better pain management in discharged patients, we developed a mobile phone application (Pain Guard) for providing continuous treatment information and feedback to discharged patients suffering from pain. Objective: To design, construct, and test Pain Guard in patients managing cancer pain, and evaluate the total remission rate of pain and the improvement in quality of life (QoL), in order to improve pain management for patients who receive treatment both within and outside the hospital. Methods: This randomized controlled double-arm study involved 58 patients with cancer pain symptoms. Participants were randomly assigned to a group receiving care through the Pain Guard app or to a control group who received only traditional pharmaceutical care. In a pre-test, participants were rated using a baseline cancer-pain assessment and QoL evaluation. During treatment, the consumption levels of analgesic drugs were recorded every week. After a 4-week study period, another round of cancer-pain assessment and QoL evaluation was conducted. The system’s usability, feasibility, compliance, and satisfaction were also assessed. Our primary outcome was remission rate of pain, and secondary outcomes were compliance with medication, improvements in QoL, frequency of breakthrough cancer pain (BTcP), incidence of adverse reactions, and satisfaction of patients. Results: All participants (58 patients) successfully completed the study. There were no significant differences in baseline pain score or baseline QoL scores between groups (P>0.10). At the end of the study, the rate of pain remission in the trial group was significantly higher than that in the control group (P<.01). The frequency of BTcP in the trial group was considerably lower than that in the control group (P<.01). The rate of medication compliance in the trial group was considerably higher than that in the control group (P<.01). Improvements in QoL scores in the trial group were also significantly higher than those in the control group (P<.01). The incidence of adverse reactions in the trial group (7/31) was much lower than that in the control group (12/27). The 31 participants in the trial group completed a satisfaction survey regarding Pain Guard: 23 (74%) indicated that they were satisfied with receiving pharmaceutical care by Pain Guard, 8 (26%) indicated that they were somewhat satisfied, 2 (6%) indicated neutral feelings, 1 (3%) indicated that they were somewhat dissatisfied, and no participants indicated that they were very dissatisfied. Conclusions: Pain Guard was effective for the management of pain in discharged patients with cancer pain, and its operability was effective and easily accepted by patients. Clinical Trial: identifier: ChiCTR1800016066